UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION I
475 ALLENDALE ROAD
KING OF PRUSSIA, PENNSYLVANIA 19406-1415

January 18, 2007

Docket No. 03003011 License No. 37-01873-01
Control No. 139540

Richard M. Sukenik
Vice President
Conemaugh Valley Memorial Hospital
1086 Franklin Street
Johnstown, PA 15905-4398

SUBJECT: CONEMAUGH VALLEY MEMORIAL HOSPITAL, LICENSE AMENDMENT, CONTROL NO. 139540

Dear Mr. Sukenik:

This refers to your license amendment request. Enclosed with this letter is the amended license removing the depleted uranium. Please note that the failure to retain transfer documentation for this licensed material is a violation of 10 CFR 40.61(a), which will be addressed in future correspondence.

Please review the enclosed document carefully and be sure that you understand and fully implement all the conditions incorporated into the amended license. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region I Office, Licensing Assistance Team, (610) 337-5239, so that we can provide appropriate corrections and answers.

An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14).

Current NRC regulations and guidance are included on the NRC's website at www.nrc.gov; select **Nuclear Materials; Medical, Academic, and Industrial Uses of Nuclear Material;** then **Toolkit Index Page.** Or you may obtain these documents by contacting the Government Printing Office (GPO) toll-free at 1-888-293-6498. The GPO is open from 7:00 a.m. to 8:00 p.m. EST, Monday through Friday (except Federal holidays).

Thank you for your cooperation.

Sincerely,

Original signed by Penny Lanzisera

Penny Lanzisera
Senior Health Physicist
Medical Branch
Division of Nuclear Materials Safety

Enclosure:
Amendment No. 64

cc:
Gregory A. Hay, Radiation Safety Officer

DOCUMENT NAME: C:\FileNet\ML070240110.wpd

SUNSI Review Complete: PLanzisera
After declaring this document "An Official Agency Record" it **will** be released to the Public.

To receive a copy of this document, indicate in the box: "**C**" = Copy w/o attach/encl "**E**" = Copy w/ attach/encl "**N**" = No copy

OFFICE	DNMS/RI	N	DNMS/RI		DNMS/RI			
NAME	PLanzisera ***/PAN/***							
DATE	1/18/07							

OFFICIAL RECORD COPY

Amendment No. 64

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with the letter dated September 29, 2006,
1. Conemaugh Valley Memorial Hospital	3. License number 37-01873-01 is amended in its entirety to read as follows:
2. 1086 Franklin Street Johnstown, Pennsylvania 15905-4398	4. Expiration date June 30, 2011
	5. Docket No. 030-03011 Reference No. 37-05272-02 / 37-05501-02

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 2 curies
D. Any byproduct material permitted by 10 CFR 35.400	D. Sealed Sources (AEA Technology Models 6500-6504; Mills Biopharmaceutical Model I-125SL; 3M Model 6711; Bard Brachytherapy Model STM-1251; Best Medical Models 2301-2316; Amersham/Medi+Physics Model 6702; Theragenics I-Seed Model 125.S06; International Brachytherapy InterSource Model I125L)	D. 2 curies
E. Iodine 125	E. Liquid Iotrex as part of the GliaSite RTS system	E. 8 curies

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
37-01873-01

Docket or Reference Number
030-03011/37-05272-02/37-05501-02

Amendment No. 64

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
B. Any imaging and localization study permitted by 10 CFR 35.200.
C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
E. For brachytherapy use in the Cytyc Surgical Products II GliaSite Radiotherapy System.

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 1086 Franklin Street, Johnstown, Pennsylvania; at the Good Samaritan Hospital, 1020 Franklin Street, Johnstown, Pennsylvania; and 320 Main Street, Johnstown, Pennsylvania.

11. The Radiation Safety Officer for this license is Gregory A. Hay, M.S.

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical use as indicated:

Authorized Users	Material and Use
Jonathan I. Abrahams, M.D.	35.100; 35.200; 35.300
Lawrence M. McNiesh, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for diagnostic studies
Harold L. Ringler, Jr., M.D.	35.100; 35.200; 35.300
Howard I. Forman, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for diagnostic studies
Anthony J. Scuderi, M.D.	35.100; 35.200; 35.300
Anwar Hussain, M.D.	35.200; Oral administration of sodium iodide iodine-131 for diagnostic studies
Gary Scott Kramer, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for diagnostic studies
Charles Oschwald, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for diagnostic studies

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
37-01873-01

Docket or Reference Number
030-03011/37-05272-02/37-05501-02

Amendment No. 64

Authorized Users	Material and Use
Arthur P. Ciacchella, M.D.	35.100; 35.200; 35.300
William E. Palmer, M.D.	35.100; 35.200; 35.300
Patrick W. Wolfe, M.D.	35.100; 35.200; 35.300
William T. Herbick, M.D.	35.100; 35.200; 35.300
William T. Corey, M.D.	35.100; 35.200; 35.300, except oral administration of greater than 33 millicuries of sodium iodide I-131
Richard W. Antemann, M.D.	35.300; 35.400; Iodine 125 for use in the GliaSite RTS System
David Stefanik, M.D.	35.300; 35.400; Iodine 125 for use in the GliaSite RTS System
Claude Harmon, M.D.	35.300; 35.400; Iodine 125 for use in the GliaSite RTS System

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
37-01873-01

Docket or Reference Number
030-03011/37-05272-02/37-05501-02

Amendment No. 64

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A.	Letter dated November 1, 1990	
B.	Letter dated January 16, 1998	
C.	Application dated February 8, 2001	(ML010570141)
D.	Letter dated June 12, 2001	(ML011730382)
E.	Amendment application dated February 12, 2002	(ML020500714)
F.	Letter dated October 25, 2002	(ML023110104)
G.	Letter dated December 29, 2003	(ML040400466)
H.	Letter dated July 6, 2005, except depleted uranium	(ML051890499)
I.	Letter dated March 2, 2006	(ML060750829)
J.	Letter dated May 4, 2006	(ML061440452)
K.	Letter dated July 21, 2006	(ML062140464)
L.	Letter dated August 1, 2006	(ML062200330)

For the U.S. Nuclear Regulatory Commission

Date January 18, 2007

By ***Original signed by Penny Lanzisera***

Penny Lanzisera
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406